SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "LAR1:gu ;mspu:(researchreview);pers:(Olsson Bob 1969)"

Sökning: LAR1:gu > Forskningsöversikt > Olsson Bob 1969

  • Resultat 1-8 av 8
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  •  
2.
  •  
3.
  •  
4.
  • Mattsson, Niklas, 1979-, et al. (författare)
  • Growth factors in Parkinson's disease.
  • 2011
  • Ingår i: Biomarkers in medicine. - 1752-0363. ; 5:2, s. 201
  • Forskningsöversikt (refereegranskat)
  •  
5.
  • Mattsson, Niklas, 1979-, et al. (författare)
  • It is all about clearance.
  • 2011
  • Ingår i: Biomarkers in medicine. - 1752-0363. ; 5:2
  • Forskningsöversikt (refereegranskat)
  •  
6.
  •  
7.
  • Olsson, Bob, 1969-, et al. (författare)
  • Biomarker-based dissection of neurodegenerative diseases.
  • 2011
  • Ingår i: Progress in neurobiology. - 1873-5118. ; 95:4
  • Forskningsöversikt (refereegranskat)abstract
    • The diagnosis of neurodegenerative diseases within neurology and psychiatry are hampered by the difficulty in getting biopsies and thereby validating the diagnosis by pathological findings. Biomarkers for other types of disease have been readily adopted into the clinical practice where for instance troponins are standard tests when myocardial infarction is suspected. However, the use of biomarkers for neurodegeneration has not been fully incorporated into the clinical routine. With the development of cerebrospinal fluid (CSF) biomarkers that reflect pathological events within the central nervous system (CNS), important clinical diagnostic tools are becoming available. This review summarizes the most promising biomarker candidates that may be used to monitor different types of neurodegeneration and protein inclusions, as well as different types of metabolic changes, in living patients in relation to the clinical phenotype and disease progression over time. Our aim is to provide the reader with an updated lexicon on currently available biomarker candidates, how far they have come in development and how well they reflect pathogenic processes in different neurodegenerative diseases. Biomarkers for specific pathogenetic processes would also be valuable tools both to study disease pathogenesis directly in patients and to identify and monitor the effect of novel treatment strategies.
  •  
8.
  • Zetterberg, Henrik, 1973-, et al. (författare)
  • Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease.
  • 2010
  • Ingår i: Alzheimer's research & therapy. - 1758-9193. ; 2:6
  • Forskningsöversikt (refereegranskat)abstract
    • ABSTRACT: In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment response in patients. To help bridge the gap between disease models and large and costly clinical trials with high failure rates, biomarkers for the intended biochemical drug effect may be of value. Such biomarkers may be called 'theragnostic'. Here, we review the literature addressing the prospective value of these biomarkers.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-8 av 8
 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy